- January 25, 2022
- Posted by: OptimizeIAS Team
- Category: DPN Topics
Subject – Science and Tech
Context – ‘Omicron may not evade all monoclonal antibodies’
- Monoclonal antibodies are laboratory-made proteins that mimic the immune system’s ability to fight off harmful pathogens such as viruses.
- Several past studies have shown that such antibodies are unsuccessful in neutralising Omicron.
- Monoclonal antibodies are among the most promising treatments for mild to moderate COVID-19, the disease caused by the novel coronavirus SARS-CoV-2.
- Monoclonal antibodies are just like your body’s antibodies but selected for their strong ability to resist the virus. They are produced like a medication and help your body fight illness.
- In 2020, the Food and Drug Administration issued an emergency use authorization to permit monoclonal antibodies as a treatment option for COVID-19.
To know about Monoclonal Antibody Therapy, please refer September 2021 DPN.